

Clinical trials of anticoagulant for acute myocardial infarction in all type of patients

TrialResults-center www.trialresultscenter.org

1 oral anticoagulant

Trial	Treatments	Patients	Trials design and methods
coumadin vs control (on top of aspirin)			
ASPECT-2 (coumadin+ASA vs ASA) , 2002 n=298/289 follow-up: 1 year	coumadin(INR mean 2.4) +aspirin versus aspirin	Acute MI, unstable angina	Parallel groups open the Netherlands
warfarin vs control (on top of aspirin)			
WARIS , 1999 n=1208/1206 follow-up: 65279;37 months	warfarin 2.84.8 versus placebo	survivors of acute myocardial infarction	Parallel groups double blind
APRICOT-2 , 2002 n=135/139 follow-up: 3 months	moderate-intensity coumarin target INR 2-3 (+aspirin) versus aspirin	Acute MI after thrombolytics	Parallel groups open the Netherlands
CARS (warafirin 3mg) , 1997 n=5410/3393 follow-up: 14 months	warfarin fixed dose 3mg/d + 80 mg ASA versus aspirin 160 mg/d	AMI	Parallel groups double blind North America
CARS (warfarin 1mg) , 1997 n=2028/3393 follow-up: 14 months	warfarin 1mg/d + aspirin 80mg/d versus aspirin 160 mg/d	patients who had had myocardial infarction	Parallel groups double blind North America
CHAMP , 2002 n=2522/2537 follow-up: 2.7 years	warfarin target INR 1.5-2.5 + aspirin 81 mg daily versus aspirin 162 mg/d	AMI (patients enrolled within 14 days of infarction)	Parallel groups open US
LoWASA , 2004 n=1659/1641 follow-up: 5 years	warfarin fixed dose 1.25mg/d + ASA 75mg/d versus aspirin alone	AMI	Parallel groups open Sweden
WARIS II (warfarin+ASA) , 2002 n=4927/4669 follow-up: 4 years	warfarin target INR 2-2.5 +ASA 75mg/d versus ASA 160mg/d	patients hospitalized for acute myocardial infarction	Parallel groups open Norway

continued...

Trial	Treatments	Patients	Trials design and methods
Zibaenezhad , 2004 n=70/70 follow-up: 1 year	Warfarin target INR 65279;23 +aspirin versus aspirin 100 mg/day	Acute MI	Parallel groups open
any anticoagulant vs placebo			
Sixty Plus reinfarction Study , 1980 n=NA follow-up: 2 years	anticoagulant versus placebo	over 60 years of age	Parallel groups double blind
coumadin vs placebo			
ASPECT , 1994 n=1700/1704 follow-up: 37 months (range 6-76)	nicoumalone or phenprocoumon, target INR 2.84.8 versus placebo	hospital survivors of myocardial infarction	Parallel groups double blind
phenprocoumon vs placebo			
German-Austrian Study Group (oac vs pbo) , 1980 n=320/309 follow-up: 2 years	phenprocoumon versus placebo	patients who had survived a myocardial infarction for 30-42 days	Parallel groups double blind
warfarin vs placebo (on top of aspirin)			
Williams , 1997 n=6/5 follow-up: 2.5 months	warfarin target INR 65279;22.5 +aspirin versus placebo +aspirin	Acute MI, unstable angina	Parallel groups double blind
any anticoagulant vs aspirin			
EPSIM , 1982 n=652/651 follow-up: 29 months (range 6-59)	anticoagulant versus aspirin 500mg three times daily	patients surviving myocardial infarction	Parallel groups open
coumadin vs aspirin			
ASPECT-2 (coumadin alone) , 2002 n=325/336 follow-up: 1 year (range 0-26 months)	coumadin (phenprocoumon or acenocoumarol) target INR 3-4 versus aspirin 80mg daily	Acute MI, unstable angina	Parallel groups open the Netherlands
phenprocoumon vs aspirin			
German-Austrian Study Group (oac vs asp) , 1980 n=320/317 follow-up: 2 years	phenprocoumon versus aspirin 1.5 g daily	patients who had survived a myocardial infarction for 30-42 days	Parallel groups double blind
warfarin vs aspirin			
WARIS II (warfarin alone) , 2002 n=1216/1206 follow-up: 48 months	warfarin target INR 2.8-4.2 versus ASA 160mg/d	patients hospitalized for acute myocardial infarction	Parallel groups NA Norway

References

ASPECT-2 (coumadin+ASA vs ASA), 2002:

van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. *Lancet* 2002;360:109-13 [[12126819](#)]

WARIS, 1999:

Smith P, Arnesen H, Holme I The effect of warfarin on mortality and reinfarction after myocardial infarction. *N Engl J Med* 1990;323:147-52 [[2194126](#)]

APRICOT-2, 2002:

Brouwer MA, van den Bergh PJ, Aengevaeren WR, Veen G, Luijten HE, Hertzberger DP, van Boven AJ, Vromans RP, Uijen GJ, Verheugt FW Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. *Circulation* 2002;106:659-65 [[12163424](#)]

CARS (warafirin 3mg), 1997:

Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. *Lancet* 1997;350:389-96 [[9259652](#)]

CARS (warfarin 1mg), 1997:

Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. *Lancet* 1997;350:389-96 [[9259652](#)]

CHAMP, 2002:

Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. *Circulation* 2002;105:557-63 [[11827919](#)]

LoWASA, 2004:

Herlitz J, Holm J, Peterson M, Karlson BW, Haglid Evander M, Erhardt L Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. *Eur Heart J* 2004;25:232-9 [[14972424](#)]

WARIS II (warfarin+ASA), 2002:

Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H Warfarin, aspirin, or both after myocardial infarction. *N Engl J Med* 2002;347:969-74 [[12324552](#)]

Zibaenezhad, 2004:

Zibaenezhad MJ, Mowla A, Sorbi MH Warfarin and aspirin versus aspirin alone in patients with acute myocardial infarction: a pilot study. *Angiology* 2004;55:17-20 [[14759085](#)]

Sixty Plus reinfarction Study, 1980:

A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. *Lancet* 1980;2:989-94 [[6107674](#)]

ASPECT, 1994:

Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. *Lancet* 1994;343:499-503 [[7906757](#)]

German-Austrian Study Group (oac vs pbo), 1980:

Breddin K, Loew D, Lechner K, Oberla K, Walter E The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group. *Circulation* 1980 Dec;62:V63-72 [[6777073](#)]

Williams, 1997:

Williams MJ, Morison IM, Parker JH, Stewart RA Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. *J Am Coll Cardiol* 1997;30:364-9 [[9247506](#)]

EPSIM, 1982:

A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. *N Engl J Med* 1982;307:701-8 [[7050710](#)]

ASPECT-2 (coumadin alone), 2002:

van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. *Lancet* 2002;360:109-13 [[12126819](#)]

German-Austrian Study Group (oac vs asp), 1980:

Breddin K, Loew D, Lechner K, Oberla K, Walter E The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group. *Circulation* 1980;62:V63-72 [[6777073](#)]

WARIS II (warfarin alone), 2002:

Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H Warfarin, aspirin, or both after myocardial infarction. *N Engl J Med* 2002;347:969-74 [[12324552](#)]

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.